Table 1.

Characteristics of decitabine-sensitive and -resistant HMCLs

HMCL nameIL-6 dependenceaOriginbDiseasecPatient sampledGenderIsotypet(14q32 or 22q11)Target genesRasTP53CD45HMCL classification
Decitabine-resistant HMCLs
 XG-6++MNMMPBFGlt(16;22)c-Mafwtwt+CTA/MF
 XG-20++MNPCLPBMlt(4;14)MMSETwtabnMS
 XG-13++MNPCLPBMGlt(14;16)c-Mafwtabn+MF
 SKMM2COPCLPBMGkt(11;14)CCND1wtabnCD-1
 LP1COMMPBFGlt(4;14)MMSET/FGFR3wtabnMS
Decitabine-sensitive HMCLs
 XG-12++MNPCLPBFlt(14;16)c-Mafmutwt+CTA/MF
 XG-16++MNPCLPBMknonenonemutabn+CTA/FRZB
 XG-19++MNPCLPBFAlt(14;16)c-Mafwtwt+CTA/MF
 JJN3COMMPEFAkt(14;16)c-Mafmutabn+/−MF
 RPMI8226COMMPBMGlt(14;16)c-MafmutabnMF

Abbreviations: AF, ascitic fluid; BM, bone marrow; CO, collected; MN, Montpellier or Nantes; PB, peripheral blood; PCL, plasma cell leukemia; PCT, plasmacytoma; PE pleural effusion.

  • a++, if growth is strictly dependent on adding exogenous IL-6; +, if dependent on adding exogenous IL-6; −, if not.

  • bOrigin of the HMCL.

  • cDisease at diagnosis.

  • dOrigin of the sample.